Gastroesophageal reflux disease is commonly associated with burning chest pain, regurgitation and irritation of the esophagus, but the disorder begins with changes that are far smaller than the symptoms they eventually produce. One of the earliest microscopic signs is the appearance of dilated intercellular spaces, or DIS, in the esophageal lining. These widened gaps between neighboring epithelial cells weaken the tissue’s barrier function, allowing acid, digestive enzymes and other irritants to penetrate more deeply. A study by Schiralli Lester, Huang, Barravecchia and colleagues, published in Gene Therapy, describes a gene therapy strategy intended to prevent this structural damage before it develops into persistent reflux-related disease.
The inner surface of the esophagus is covered by stratified squamous epithelial cells that must perform two seemingly opposing tasks. They need to withstand repeated mechanical stress as food passes through, while also limiting the movement of corrosive material from the esophageal lumen into underlying tissue. Under healthy conditions, adjacent cells are connected by specialized junctional complexes, including tight junctions and adherens junctions. These structures regulate the passage of water and dissolved molecules through the spaces between cells. When reflux exposes the epithelium to acid and bile components, the junctional system can become disrupted, causing the spaces between cells to expand.
DIS is therefore more than a microscopic curiosity. It represents a loss of epithelial integrity and may contribute directly to the abnormal sensitivity experienced by people with reflux. The enlarged spaces can permit hydrogen ions and inflammatory mediators to reach sensory nerve endings beneath the epithelium. This process may help explain why some patients experience severe heartburn even when visible erosions are limited or absent. It also provides researchers with a measurable cellular feature that can be used to evaluate whether a treatment is protecting the esophageal barrier.
The gene therapy approach described in the report is designed to intervene at the level of the cells’ molecular machinery rather than simply neutralizing acid after reflux has occurred. Gene therapies generally work by introducing genetic instructions that alter the activity of target cells. Those instructions can increase production of a protective protein, restore a pathway damaged by disease or reduce the expression of a molecule that drives tissue injury. In the context of reflux, the objective is to preserve the proteins and signaling systems that hold epithelial cells together, thereby preventing the intercellular spaces from widening.
This strategy reflects a shift in the way reflux disease might be treated. Proton-pump inhibitors and related medicines reduce gastric acidity, and they remain important tools for controlling symptoms and allowing damaged tissue to heal. However, acid suppression does not necessarily repair every molecular defect in the epithelial barrier, nor does it prevent non-acidic components of reflux from reaching the esophagus. A therapy that strengthens the lining itself could, in principle, address a fundamental vulnerability rather than treating only one chemical component of the refluxate.
At the cellular level, the success of such an intervention depends on precise control. The esophageal epithelium is continually renewed, meaning that therapeutic genetic instructions must reach the relevant cells and remain active long enough to influence tissue repair. The treatment must also avoid excessive or prolonged expression, which could disturb normal cell growth or differentiation. Researchers therefore assess not only whether a gene therapy reduces DIS, but also whether it maintains the organization of epithelial layers, supports junctional protein localization and avoids unwanted inflammatory responses.
The reported work is significant because it focuses on prevention of a defining structural change in gastroesophageal reflux disease. Rather than waiting for erosions, ulcers or long-term remodeling to appear, the approach targets the barrier defect at an earlier stage. If the epithelial seal remains intact, fewer irritants may reach deeper tissues, potentially reducing the cycle of injury, inflammation and heightened sensitivity that can sustain chronic symptoms. The concept could also help clarify whether DIS is merely a consequence of reflux or an active contributor to disease progression.
As with all gene therapy research, however, the path from experimental evidence to clinical treatment is substantial. A candidate therapy must be evaluated for delivery efficiency, durability, tissue specificity and safety. The esophagus is exposed to constant mechanical movement and to material passing through the digestive tract, factors that may complicate local administration. Researchers will also need to determine how the intervention performs in the presence of established inflammation, repeated reflux episodes and the biological differences between patients. Long-term studies will be essential to establish whether the treatment produces lasting protection without altering normal epithelial renewal.
The study arrives as scientists increasingly view barrier tissues as active therapeutic targets. The skin, intestine, lungs and blood vessels are all protected by cellular junctions whose failure can initiate or amplify disease. Applying gene therapy to the esophageal lining extends that logic to a condition traditionally managed through acid control, lifestyle changes and surgery in severe cases. By addressing the microscopic architecture of the barrier, the new approach opens a potential route toward treatments that do more than suppress symptoms. It suggests that protecting the esophagus may ultimately depend on giving its cells the genetic support needed to maintain their defenses against reflux.
Subject of Research: Gene therapy to prevent dilated intercellular spaces in the esophageal epithelium, a hallmark of gastroesophageal reflux disease
Article Title: A gene therapy approach to prevent dilated intercellular space, a hallmark of gastroesophageal reflux disease
Article References: Schiralli Lester, G.M., Huang, J., Barravecchia, M. et al. “A gene therapy approach to prevent dilated intercellular space, a hallmark of gastroesophageal reflux disease.” Gene Therapy (2026). https://doi.org/10.1038/s41434-026-00634-0
Image Credits: AI Generated
DOI: 10.1038/s41434-026-00634-0
Keywords: Gene therapy, gastroesophageal reflux disease, GERD, dilated intercellular spaces, esophageal epithelium, epithelial barrier, tight junctions, reflux injury, molecular medicine
Tags: dilated intercellular spaces in reflux diseaseearly microscopic signs of GERDesophageal epithelial cell junctionsGene therapy for esophageal barrier protectiongene therapy strategies for barrier integrityimpact of acid and bile on esophageal epithelial cellsmolecular mechanisms of esophageal barrier breakdownnovelpreventive treatments for reflux-related esophageal damagerole of intercellular space dilation in reflux pathologystructural tissue damage prevention in acid refluxtight junctions and adherens junctions in esophageal tissue
